Blood rheology changes during bezafibrate treatment.
To evaluate the effect of bezafibrate on the haemorheological pattern, 30 atherosclerotic non-diabetic patients were enlisted in a double-blind, comparative, parallel group trial with bezafibrate (600 mg daily) or placebo being randomly assigned. The 45-day treatment period was preceded by a three week pharmacological wash-out. Haemorheological parameters such as whole-blood, plasma and serum viscosity, haematocrit, fibrinogen, fibrinogen/albumin ratio and erythrocyte filterability were evaluated before and at the end of treatment. The results showed no change in haemorheological determinants in the placebo-treated group but a significant reduction in whole-blood viscosity, in haematocrit, in fibrinogen and fibrinogen/albumin ratio was observed in the bezafibrate treated patients. No variation was present in the plasma and serum viscosity and in the erythrocyte filterability.
Caimi
G
G
Francavilla
G
G
Romano
A
A
Catania
A
A
Santonocito
G
G
Sarno
A
A
D000368:Aged; D001161:Arteriosclerosis / Q000097:blood* / Q000188:drug therapy; D001629:Bezafibrate / Q000627:therapeutic use*; D001809:Blood Viscosity / Q000187:drug effects*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005340:Fibrinogen / Q000032:analysis; D006400:Hematocrit; D006801:Humans; D008875:Middle Aged; D011897:Random Allocation
D005340:Fibrinogen; D001629:Bezafibrate